Temozolomide News and Research

RSS

Cancer Research UK and AstraZeneca announce innovative deal for promising anti-cancer compound

Cancer Research UK and Cancer Research Technology (CRT) - the charity's development and commercialisation arm - today announced an innovative new arrangement to progress into clinical development a potential anti-cancer compound from AstraZeneca.

19 May 2008

Mouse model tightly matches pediatric tumor syndrome, will speed drug hunt

Frustrated by the slow pace of new drug development for a condition that causes pediatric brain tumors, a neurologist at Washington University School of Medicine in St. Louis decided to try to fine-tune the animal models used to test new drugs.

3 Mar 2008

Investigational treatment for advanced melanoma to be studied

University of Illinois at Chicago researchers are participating in a multi-center research trial to evaluate the safety and effectiveness of Allovectin-7, an investigational treatment for advanced melanoma.

10 Jan 2008

Advanced melanoma - new treatment

20 Dec 2007

Radiation plus chemo quadruples survival time for fatal brain cancer

Over four times as many patients with a rapidly fatal type of brain cancer, glioblastoma multiforme (GBM), who are treated with the chemotherapy drug temozolomide (TMZ) and radiation therapy, can live for four years after diagnosis, compared to those who receive only radiation treatment, according to updated results of a large, international trial presented at the Plenary I session on October 29, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.

29 Oct 2007

New anti-cancer drug made from corn lillies kills brain tumor stem cells

A drug that shuts down a critical cell-signaling pathway in the most common and aggressive type of adult brain cancer successfully kills cancer stem cells thought to fuel tumor growth and help cancers evade drug and radiation therapy, a Johns Hopkins study shows.

30 Aug 2007

Barr confirms patent challenge of TEMODAR

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patent listed for Schering Corporation's TEMODAR (Temozolomide) 5mg, 20mg, 100mg & 250mg capsules.

25 Jul 2007

Chemotherapy may enhance the effectiveness of the vaccines

Chemotherapy temporarily hinders the body's immune response, creating a concern that it may interfere with the promising new cancer vaccines being used against brain tumors.

5 Jun 2007

Chemotherapy drug temozolomide shrinks brain tumors

Cancerous brain tumors appear to respond favorably to the drug temozolomide when used as primary chemotherapy after surgery, and the treatment appears to work best in people missing a certain gene, according to a study published in the May 22, 2007, issue of Neurology, the scientific journal of the American Academy of Neurology.

22 May 2007

Promising chemo, therapeutic viruses, cutting-edge surgery debut at M. D. Anderson Cancer Center

Brain tumor specialists at The University of Texas M. D. Anderson Cancer Center are poised on the brink of a new era.

10 May 2006

New hope for patients with metastatic melanoma

Patients with metastatic melanoma (MM) have new hope, says a recently published study by Mayo Clinic Cancer Center. The study, which shows the combination of paclitaxel and carboplatin (PC) appears to be effective for MM when traditional treatments have failed, is in this month's issue of Cancer.

6 Jan 2006

Study examines biomarkers for response to erlotinib in glioma

Researchers have found two biomarkers that, in patients with a malignant type of brain tumor called glioblastoma multiforme, were associated with response to the cancer drug erlotinib (Tarceva).

14 Jun 2005

European approval of Temodal (temozolomide) capsules for treatment of glioblastoma multiforme

Schering-Plough announced today that the European Commission has granted approval of Temodal (temozolomide) Capsules for first-line use for the treatment of patients with newly diagnosed glioblastoma multiforme (GBM), the most common and aggressive form of primary brain cancer.

10 Jun 2005

Approval for Temodar (temozolomide) capsules for newly diagnosed glioblastoma multiforme

Schering-Plough today reported that the U.S. Food and Drug Administration (FDA) has granted approval for Temodar (temozolomide) Capsules for use in combination with radiotherapy for the treatment of adult patients with newly diagnosed glioblastoma multiforme (GBM), a form of malignant brain cancer.

16 Mar 2005

New chemotherapy gives hope to brain tumour patients

A large international study conducted by the European Organisation for Research and Treatment of Cancer (EORTC) in collaboration with the National Cancer Institute of Canada (NCIC) Clinical Trials Group demonstrated that the addition of a novel chemotherapy agent, Temozolomide (brand name: Temodal®) to radiation therapy increases survival in patients suffering from glioblastoma, a very aggressive form of a brain tumour.

9 Mar 2005

Trial shows which brain cancer patients benefit from temozolomide

An international team of scientists and cancer specialists has identified which patients with the deadly form of brain tumours called glioblastomas are likely to live longer if they are treated with temozolomide, and which patients are likely to get only marginal, if any, benefit.

28 Sep 2004

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

50,000 people or 10% of the 500,000 people in the U.S with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery for coverage of life saving drugs.

26 Jun 2004